Parc Technologique de Lyon
8, allée Irène Joliot Curie
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life.
CEO: Étienne Binant
CMO: William Spotnitz
CSO: Valerie Centis
CFO: Joao-Paulo Alves
11 articles with Biom'up
Successful review of HEMOBLAST Bellows’ performance and safety profile as well as Biom’up’s Quality Management System by the Australian Therapeutic Goods Administration (TGA)
Approval of 2019 H1 interim results postponed: Board of Directors pursues review of options available to the Company
Estimated total sales of HEMOBLAST™ Bellows for the first nine months of 2019 are expected to show strong growth at €2.5 million (compared to €1.5 million for the first half of 2019 and €0.6 million for the full year 2018) and are expected to be on track to achieve the 2019 revenue guidance range of €4.0-€4.5 million
Biom’up SA announced that Patrice Ferrand was appointed CEO, replacing Dr. Jan Ohrstrom. Dr. Ohrstrom, who was appointed CEO in May of this year, remains Chairman of the Board, a role in which he has served for the Company since 2015.
Biom’up Provides Business Update for the First Half of 2019 and confirms its Revenue Guidance for the year
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal
Biom’up SA, specializing in surgical hemostasis, announced a change in the Company’s leadership position.
Biom’up is providing for the first time, full-year 2019 guidance for global sales of HEMOBLAST Bellows in the range of €4.0-4.5 million.
Biom'up announced its full-year results for the year ending December 31, 2018, as approved by the Company's Board of Directors on April 29, 2019, and provided an update on its operations.
Biom’up announced that the U.S. Food and Drug Administration approved the IDE application for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate developed by the Company for managing minimal and mild levels of bleeding during surgical procedures.
Biom’up announces first US sales in laparoscopy for HEMOBLASTTM Bellows and the signing of an exclusive distribution agreement for HEMOBLASTTM Bellows in Australia
Major framework agreement signed with Life Healthcare Distribution (“LHC”) for the exclusive distribution of HEMOBLAST Bellows in the sizeable and growing Australian market
Biom'up completes its Board of Directors with the nomination of Dr. Peter Byloos to support its international growth
Biom'up today announces Dr. Peter Byloos' co-optation to its Board of Directors as an independent director.
Biom'Up announces today that it has received FDA marketing approval for HEMOBLAST Bellows, its flagship product, 7 months ahead of schedule.